Detecting cancer biomarkers in blood: Challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids

Jean M. Lewis, Daniel P. Heineck, Michael (Mike) Heller

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

As we move into the era of individualized cancer treatment, the need for more sophisticated cancer diagnostics has emerged. Cell-free (cf) nucleic acids (cf-DNA, cf-RNA) and other cellular nanoparticulates are now considered important and selective biomarkers. There is great hope that blood-borne cf-nucleic acids can be used for liquid biopsies, replacing more invasive tissue biopsies to analyze cancer mutations and monitor therapy. Conventional techniques for cf-nucleic acid biomarker isolation from blood are generally time-consuming, complicated and expensive. They require relatively large blood samples, which must be processed to serum or plasma before isolation of biomarkers can proceed. Such cumbersome sample preparation also limits the widespread use of powerful, downstream genomic analyses, including PCR and DNA sequencing. These limitations also preclude rapid, point-of-care diagnostic applications. Thus, new technologies that allow rapid isolation of biomarkers directly from blood will permit seamless sample-to-answer solutions that enable next-generation point-of-care molecular diagnostics.

Original languageEnglish (US)
Pages (from-to)1187-1200
Number of pages14
JournalExpert Review of Molecular Diagnostics
Volume15
Issue number9
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Point-of-Care Systems
Molecular Pathology
Tumor Biomarkers
Nucleic Acids
Biomarkers
Biopsy
Neoplasms
DNA Sequence Analysis
Blood Cells
RNA
Technology
Polymerase Chain Reaction
Mutation
DNA
Serum

Keywords

  • biomarkers
  • cancer
  • cell-free DNA
  • cell-free RNA
  • exosomes
  • liquid biopsy
  • molecular diagnostics
  • nanoparticulates
  • point-of-care
  • sample preparation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Detecting cancer biomarkers in blood : Challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids. / Lewis, Jean M.; Heineck, Daniel P.; Heller, Michael (Mike).

In: Expert Review of Molecular Diagnostics, Vol. 15, No. 9, 01.01.2015, p. 1187-1200.

Research output: Contribution to journalReview article

@article{322f026319644ec28cc7cd5ba67040e1,
title = "Detecting cancer biomarkers in blood: Challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids",
abstract = "As we move into the era of individualized cancer treatment, the need for more sophisticated cancer diagnostics has emerged. Cell-free (cf) nucleic acids (cf-DNA, cf-RNA) and other cellular nanoparticulates are now considered important and selective biomarkers. There is great hope that blood-borne cf-nucleic acids can be used for liquid biopsies, replacing more invasive tissue biopsies to analyze cancer mutations and monitor therapy. Conventional techniques for cf-nucleic acid biomarker isolation from blood are generally time-consuming, complicated and expensive. They require relatively large blood samples, which must be processed to serum or plasma before isolation of biomarkers can proceed. Such cumbersome sample preparation also limits the widespread use of powerful, downstream genomic analyses, including PCR and DNA sequencing. These limitations also preclude rapid, point-of-care diagnostic applications. Thus, new technologies that allow rapid isolation of biomarkers directly from blood will permit seamless sample-to-answer solutions that enable next-generation point-of-care molecular diagnostics.",
keywords = "biomarkers, cancer, cell-free DNA, cell-free RNA, exosomes, liquid biopsy, molecular diagnostics, nanoparticulates, point-of-care, sample preparation",
author = "Lewis, {Jean M.} and Heineck, {Daniel P.} and Heller, {Michael (Mike)}",
year = "2015",
month = "1",
day = "1",
doi = "10.1586/14737159.2015.1069709",
language = "English (US)",
volume = "15",
pages = "1187--1200",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Detecting cancer biomarkers in blood

T2 - Challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids

AU - Lewis, Jean M.

AU - Heineck, Daniel P.

AU - Heller, Michael (Mike)

PY - 2015/1/1

Y1 - 2015/1/1

N2 - As we move into the era of individualized cancer treatment, the need for more sophisticated cancer diagnostics has emerged. Cell-free (cf) nucleic acids (cf-DNA, cf-RNA) and other cellular nanoparticulates are now considered important and selective biomarkers. There is great hope that blood-borne cf-nucleic acids can be used for liquid biopsies, replacing more invasive tissue biopsies to analyze cancer mutations and monitor therapy. Conventional techniques for cf-nucleic acid biomarker isolation from blood are generally time-consuming, complicated and expensive. They require relatively large blood samples, which must be processed to serum or plasma before isolation of biomarkers can proceed. Such cumbersome sample preparation also limits the widespread use of powerful, downstream genomic analyses, including PCR and DNA sequencing. These limitations also preclude rapid, point-of-care diagnostic applications. Thus, new technologies that allow rapid isolation of biomarkers directly from blood will permit seamless sample-to-answer solutions that enable next-generation point-of-care molecular diagnostics.

AB - As we move into the era of individualized cancer treatment, the need for more sophisticated cancer diagnostics has emerged. Cell-free (cf) nucleic acids (cf-DNA, cf-RNA) and other cellular nanoparticulates are now considered important and selective biomarkers. There is great hope that blood-borne cf-nucleic acids can be used for liquid biopsies, replacing more invasive tissue biopsies to analyze cancer mutations and monitor therapy. Conventional techniques for cf-nucleic acid biomarker isolation from blood are generally time-consuming, complicated and expensive. They require relatively large blood samples, which must be processed to serum or plasma before isolation of biomarkers can proceed. Such cumbersome sample preparation also limits the widespread use of powerful, downstream genomic analyses, including PCR and DNA sequencing. These limitations also preclude rapid, point-of-care diagnostic applications. Thus, new technologies that allow rapid isolation of biomarkers directly from blood will permit seamless sample-to-answer solutions that enable next-generation point-of-care molecular diagnostics.

KW - biomarkers

KW - cancer

KW - cell-free DNA

KW - cell-free RNA

KW - exosomes

KW - liquid biopsy

KW - molecular diagnostics

KW - nanoparticulates

KW - point-of-care

KW - sample preparation

UR - http://www.scopus.com/inward/record.url?scp=84940564438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940564438&partnerID=8YFLogxK

U2 - 10.1586/14737159.2015.1069709

DO - 10.1586/14737159.2015.1069709

M3 - Review article

C2 - 26189641

AN - SCOPUS:84940564438

VL - 15

SP - 1187

EP - 1200

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 9

ER -